Positive Phase III Results Reported for Antiplatelet Agent Cangrelor
Drug prevents clotting complications during and after PCI (September 3)
A pooled analysis of three phase III clinical trials of an investigational intravenous (IV) antiplatelet drug, cangrelor (Medicines Company), has been published in The Lancet. The trials compared IV cangrelor with either oral clopidogrel or placebo for the prevention of thrombotic (clotting) complications during and after percutaneous coronary intervention (PCI).
In approximately 25,000 patients undergoing PCI, cangrelor significantly reduced the odds of the primary composite endpoint of death, myocardial infarction (MI), ischemia-driven revascularization (IDR), or stent thrombosis (ST) at 48 hours after randomization by 19% (3.8% for cangrelor vs. 4.7% for control; P = 0.0007) and stent thrombosis by 41% (P = 0.0008).
The pooled analysis also showed that the incidence of clinically important major bleeding was not increased with cangrelor. However, there were significantly more cases of transient dyspnea with cangrelor than with clopidogrel.
Cangrelor, an immediately bioavailable and reversible IV small-molecule antiplatelet agent, is in development to prevent platelet activation and aggregation that leads to thrombosis in the acute-care setting, including in patients undergoing PCI.
Source: The Medicines Company; September 3, 2013.